Acoramidis

Acoramidis (AG10) is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin) . Acoramidis (AG10) is used in the study for transthyretin amyloidosis[1][2].

Product Specifications

CAS Number

[1446711-81-4]

Product Name Alternative

AG10

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Transthyretin (TTR)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/acoramidis.html

Purity

99.23

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC=C(F)C(OCCCC2=C(C)NN=C2C)=C1

Molecular Formula

C15H17FN2O3

Molecular Weight

292.31

Precautions

H315, H319, H335

References & Citations

[1]Sravan C Penchala, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A. 2013 Jun 11;110 (24) :9992-7.|[2]Jonathan C Fox, et al. First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers. Clin Pharmacol Drug Dev. 2020 Jan;9 (1) :115-129.|[3]Stephen P Soltoff, et al. Evidence that tyrphostins AG10 and AG18 are mitochondrial uncouplers that alter phosphorylation-dependent cell signaling. J Biol Chem. 2004 Mar 19;279 (12) :10910-8.